Back to search

Article

Quantitative Systems Pharmacology Analysis of Amyloid Aggregation and Hippocampal Atrophy Trajectories in Alzheimer’s Disease by APOE4 Genotype and Valiltramiprosate/ALZ-801 Treatment

2026-08-24

Abstract excerpt

<title>Abstract</title> <p>Apolipoprotein E4 (APOE4) is a major risk factor for Alzheimer’s disease (AD). Valiltramiprosate/ALZ-801, an oral inhibitor of β-amyloid (Aβ) oligomer formation, was evaluated in APOE4/4 subjects with early AD in the APOLLOE4 Phase 3 trial. We used quantitative systems pharmacology (QSP) to characterize AD trajectories by APOE genotype and assess the effects of valiltramiprosate treatme...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
90229a3d-e53f-5c83-b1c3-2f3c338bd765
DOI
10.21203/rs.3.rs-10570608/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Quantitative Systems Pharmacology Analysis of Amyloid Aggregation and Hippocampal Atrophy Trajectories in Alzheimer’s Disease by APOE4 Genotype and Valiltramiprosate/ALZ-801 TreatmentDOI 10.21203/rs.3.rs-10570608/v1
Select a neighboring publication to make it the new centre.